Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GYRE
stocks logo

GYRE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.900
sliders
Low
16.00
Averages
18.00
High
20.00
Current: 7.900
sliders
Low
16.00
Averages
18.00
High
20.00
H.C. Wainwright
H.C. Wainwright
initiated
$18
2025-08-26
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$18
2025-08-26
initiated
Reason
H.C. Wainwright initiated coverage of Gyre Therapeutics with a Buy rating and $18 price target. The company's lead asset hydronidone is a structural analog of the anti-fibrotic drug pirfenidone and a "potent inhibitor" of fibrosis, the analyst tells investors in a research note. The firm believes Gyre is "still flying under the radar with investors" despite a "compelling" portfolio of established therapeutics.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Gyre Therapeutics Inc (GYRE.O) is 36.74, compared to its 5-year average forward P/E of 11.13. For a more detailed relative valuation and DCF analysis to assess Gyre Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
11.13
Current PE
36.74
Overvalued PE
33.02
Undervalued PE
-10.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
8.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
25.65
Undervalued EV/EBITDA
-9.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.30
Current PS
0.00
Overvalued PS
3.62
Undervalued PS
-1.01
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GYRE News & Events

Events Timeline

(ET)
2025-11-07
06:16:22
Gyre Therapeutics lowers FY25 revenue forecast to $115M-$118M from previous estimate of $118M-$128M.
select
2025-11-07
06:14:59
Gyre Therapeutics Announces Q3 Earnings Per Share of 3 Cents, Exceeding Consensus Estimate of 2 Cents
select
2025-10-15 (ET)
2025-10-15
07:03:50
Gyre Therapeutics finishes enrolling participants for Phase 3 trial of Pirfenidone capsules.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-07NASDAQ.COM
GYRE THERAPEUTICS, INC. Reports Increase in Q3 Earnings

  • Earnings Growth: GYRE THERAPEUTICS, INC. reported a profit of $3.61 million for Q3, up from $1.12 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) increased to $0.03, compared to $0.01 in the previous year.

  • Revenue Increase: Revenue for the quarter rose by 19.9% to $30.56 million, up from $25.49 million last year.

  • Financial Summary: Key financial figures include earnings of $3.61 million, EPS of $0.03, and revenue of $30.56 million, reflecting significant growth year-over-year.

[object Object]
Preview
6.0
10-17NASDAQ.COM
Fresh Strong Sell Stocks for October 17th

  • Stocks Added to Zacks Rank #5: Gyre Therapeutics, Darling Ingredients, and Cresco Labs have been added to the Zacks Rank #5 (Strong Sell) List due to significant downward revisions in their earnings estimates over the past 60 days.

  • Investment Opportunities: Despite their current rankings, these stocks were selected by Zacks experts as potential high-growth investments, with previous recommendations achieving substantial gains.

[object Object]
Preview
9.0
08-27Benzinga
Gyre Therapeutics Emerges as a Notable Player in Liver Fibrosis Drug Development

  • Gyre Therapeutics Overview: Gyre Therapeutics Inc. is a biopharmaceutical company focusing on organ fibrosis treatments, with its flagship product ETUARY being the first approved treatment for idiopathic pulmonary fibrosis in China.

  • Financial Performance: The company reported second-quarter sales of $26.78 million, falling short of expectations, but anticipates revenue growth in 2025 driven by new product launches and existing sales.

  • Hydronidone Development: Gyre's lead asset, hydronidone, has shown promising results in clinical trials for liver fibrosis and is expected to enter Phase 2 assessment in the U.S. by late 2025, with plans for accelerated approval in China.

  • Market Potential: Analysts predict significant market potential for hydronidone, estimating it could generate approximately $6 billion in annual sales by 2033, similar to the success anticipated for Madrigal Pharmaceuticals' recent liver disease treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Gyre Therapeutics Inc (GYRE) stock price today?

The current price of GYRE is 7.9 USD — it has increased 3.4 % in the last trading day.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s business?

Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

arrow icon

What is the price predicton of GYRE Stock?

Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 18.00 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s revenue for the last quarter?

Gyre Therapeutics Inc revenue for the last quarter amounts to 30.56M USD, increased 19.92 % YoY.

arrow icon

What is Gyre Therapeutics Inc (GYRE)'s earnings per share (EPS) for the last quarter?

Gyre Therapeutics Inc. EPS for the last quarter amounts to 0.03 USD, increased 200.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Gyre Therapeutics Inc (GYRE)'s fundamentals?

The market is revising Downward the revenue expectations for Gyre Therapeutics, Inc. (GYRE) for FY2025, with the revenue forecasts being adjusted by -4.46% over the past three months. During the same period, the stock price has changed by 2.73%.
arrow icon

How many employees does Gyre Therapeutics Inc (GYRE). have?

Gyre Therapeutics Inc (GYRE) has 574 emplpoyees as of December 05 2025.

arrow icon

What is Gyre Therapeutics Inc (GYRE) market cap?

Today GYRE has the market capitalization of 716.22M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free